Samsung Bioepis, Teva enter commercialization agreement on 6 biosimilar candidates
Samsung Bioepis and Teva Pharmaceutical Industries have entered into an agreement on commercializing the former’s up to six potential biosimilar candidates, including two confirmed investigational candidates, the companies said Thursday. According to Samsung Bioepis, the two sides have signed a global licensing, development and commercialization agreement for the potential candidates. Of them,…
Samsung Bioepis and Teva Pharmaceutical Industries have formed a global agreement to commercialize up to six potential biosimilar candidates, the companies announced on Thursday. This partnership will cover two confirmed investigational biosimilars, SB41 and SB44, as well as four other candidates yet to be confirmed. SB41 is based on AstraZeneca's Fasenra, a medication used to treat severe eosinophilic asthma.
SB44 is derived from Novartis' Ilaris, which is used to treat various inflammatory conditions, including rare autoinflammatory diseases. Samsung Bioepis will handle the development, regulatory registration, and manufacturing of these biosimilars, while Teva will be responsible for commercializing them across global markets, including the United States, Europe, and Canada.
The agreement also includes an option for the partnership to extend to additional territories. Samsung Bioepis stated that this collaboration strengthens their existing position in the biosimilar market.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
